Motesanib Does Not Make a Mark in NSCLC Study

by Savitha C Muppala on  April 1, 2011 at 8:07 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Motesanib, a drug meant for those cancers which are difficult to treat , has unfortunately not lived up to expectations in the phase III trial.

 Infact, it did not make any significant contribution in improving the survival rate among victims of non-small cell lung cancer (NSCLC).
 Motesanib Does Not Make a Mark in NSCLC Study
Motesanib Does Not Make a Mark in NSCLC Study

Nearly 1,090 patients with advanced nonsquamous NSCLC were part of the study.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive